source
- BioCryst to rely on external partnerships after ending internal discovery programsBioCryst Pharmaceuticals CEO Charlie Gayer told Fierce that the company remains committed to science and research even as it shuts down its internal discovery efforts. Earlier this year the firm’s…
- FDA releases weekly update on user fee letters and new HHS regulatory agendaThe FDA's latest weekly briefing highlighted the release of user fee commitment letters, which outline the agency's financial planning for upcoming fiscal periods. It also introduced a new regulat…